S9 Ep15: FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Aug 3, 2023
21:26
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Carlo-Stella discusses the FDA approval of glofitamab in relapsed/refractory DLBCL, key efficacy and safety findings from the NP30179 trial, and the benefits of glofitamab’s mechanism of action.
OncLive® On Air